Positive Correlation of Galanin with Glucose in Healthy Volunteers during an Oral Glucose Tolerance Test

Abstract

Galanin has been found in increased amounts in subjects with type 2 diabetes. The purpose of the present study was to determine the levels of galanin in healthy volunteers during an oral glucose tolerance test (OGTT). We enrolled 11 healthy volunteers, 4 males aged 48±3.56 years with BMI 27±0.5 kg/m² and 7 females aged 41.3±3.05 years with BMI 27.6±0.9 kg/m². All were in good health without cardiac, hepatic, renal or other chronic disease. None were taking any medication affecting glucose tolerance (β-blockers, thiazide diuretics, and corticoids) and none had a first degree relative with type 2 diabetes. Glucose tolerance was determined by using the International Expert Committee criteria. Blood samples were collected at 0, 30, 60, 90, 120 and 180 minutes for the measurement of plasma glucose, insulin, C-peptide and human galanin (hGal). During the OGTT, hGal exhibited a significant increase from time 0 to 90 minutes (p < 0.001) and returned to the basal values at 180 minutes, while a positive correlation of blood glucose with hGal was observed during the time scale of OGTT. A significant increase was detected both in insulin and C-peptide from the early beginning of the test at 30 minutes, which remained steady until 90 minutes, and returned gradually to the basal values at 180 minutes. No relationship was found either between hGal and serum insulin, or between hGal and serum C-peptide among the healthy subjects, during the OGTT.

tolerance - insulin - C-peptide - fasting state - homeostasis

References

• 1 Vrontakis ME. Galanin. a biologically active peptide.  Curr Drug Targets CNS Neurol Disord. 2002;  1 531-541
• 2 Greenberg GR, McDonald TJ. Effect of galanin and vagal integrity on insulin release in dogs.  Pancreas. 1988;  3 122-127
• 3 Holst JJ, Bersani M, Hvidberg A, Knigge U, Christiansen E, Madsbad S, Harling H, Kofod H. On the effects of human galanin in man.  Diabetologia. 1993;  36 653-657
• 4 McDonald TJ, Tu E, Brenner S, Zabel P, Behme M, Panchal C, Hramiak I, Barnett WB, Miller D, Dupre J. Canine, human, and rat plasma insulin responses to galanin administration: species response differences.  Am J Physiol. 1994;  266 E612-E617
• 5 Taborsky Jr GJ, Dunning BE, Havel PJ, Ahren B, Kowalyk S, Boyle MR, Verchere CB, Baskin DG, Mundinger TO. The canine sympathetic neuropeptide galanin: a neurotransmitter in pancreas, a neuromodulator in liver.  Horm Metab Res. 1999;  31 351-354
• 6 Bauer FE, Zintel A, Kenny MJ, Calder D, Ghatei MA, Bloom SR. Inhibitory effect of galanin on postprandial gastrointestinal motility and gut hormone release in humans.  Gastroenterology. 1989;  97 260-264
• 7 Wilding JP. Neuropeptides and appetite control.  Diabet Med. 2002;  19 619-627
• 8 Meczekalski B, Slopien R, Warenik-Szymankiewicz A. The concentration of galanin in postmenopausal women before and after application of hormone replacement therapy compared to women of reproductive age.  Med Sci Monit. 2001;  7 928-932
• 9 Milewicz A, Mikulski E, Bidzinska B. Plasma insulin, cholecystokinin, galanin, neuropeptide Y and leptin levels in obese women with and without type 2 diabetes mellitus.  Int J Obes Relat Metab Disord. 2000;  24 ((Suppl 2)) S152-S153
• 10 Legakis I, Matzouridis T, Moutokalakis T. Positive correlation of galanin with glucose in type 2 diabetes.  Diabetes Care. 2005;  23 759-760
• 11 Legakis IN. The role of galanin in metabolic disorders leading to type 2 diabetes mellitus.  Drug News Perspect. 2005;  18 173-177
• 12 The Expert Committee on the diagnosis and classification of diabetes mellitus . Report of the Expert Committee on the diagnosis and classification of diabetes mellitus.  Diabetes Care. 2003;  26 ((Supp 1)) S5-S20
• 13 Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models.  Biometrika. 1986;  73 13-22
• 14 Shapiro SS, Wilk MB. An analysis of variance test for normality.  Biometrika. 1965;  52 591-611
• 15 Adeghate E, Ponery AS. Large reduction in the number of galanin-immunoreactive cells in pancreatic islets of diabetic rats.  J Neuroendocrinol. 2001;  13 706-710
• 16 Manabe T, Okada Y, Sawai H, Funahashi H, Yamamoto M, Hayakawa T, Yoshimura T. Effect of galanin on plasma glucose, insulin and pancreatic glucagon in dogs.  J Int Med Res. 2003;  31 126-132
• 17 Ruczynsk J, Cybal M, Wojcikowskib C, Rekowski P. Effects of porcine galanin, galanin (1-15) NH₂ and its new analogues on glucose-induced insulin secretion.  Pol J Pharmacol. 2002;  54 133-141
• 18 Milewicz A, Mikulski E, Bidzinska B. Plasma insulin, cholecystokinin, galanin, neuropeptide Y and leptin levels in obese women with and without type 2 diabetes mellitus.  Int J Obes Relat Metab Disord. 2002;  24 ((Suppl 2)) S152-S153
• 19 Gilbey SG, Stephenson J, O’Halloran DJ, Burrin JM, Bloom SR. High-dose porcine galanin infusion and effect on intravenous glucose tolerance in humans.  Diabetes. 1989;  38 1114-1116
• 20 Tang C, Akabayashi A, Manitiu A, Leibowitz SF. Hypothalamic galanin gene expression and peptide levels in relation to circulating insulin: possible role in energy balance.  Neuroendocrinology. 1997;  65 265-275
• 21 Wang J, Leibowitz KL. Central insulin inhibits hypothalamic galanin and neuropeptide Y gene expression and peptide release in intact rats.  Brain Res. 1997;  777 231-236
• 22 Milewicz A, Bidzinska B, Mikulski E, Demissie M, Tworowska U. Influence of obesity and menopausal status on serum leptin, cholecystokinin, galanin and neuropeptide Y levels.  Gynecol Endocrinol. 2000;  14 196-203
• 23 Baranowska B, Wasilewska-Dziubinska E, Radzikowska M, Plonowski A, Roguski K. Neuropeptide Y, galanin, and leptin release in obese women and in women with anorexia nervosa.  Metabolism. 1997;  46 1384-1389
• 24 Baranowska B, Radzikowska M, Wasilewska-Dziubinska E, Roguski K, Polonowski A. Relationship among leptin, neuropeptide Y, and galanin in young women and in postmenopausal women.  Menopause. 2000;  7 149-155
• 25 Celi F, Bini V, Papi F, Ferreti A, Mencacci M, Berioli MG, Giorgi De G, Falorni A. Circulating acylated and total ghrelin and galanin in children with insulin-treated type 1 diabetes: relationship to insulin therapy, metabolic control and pubertal development.  Clin Endocrin. 2005;  63 139-145
• 26 Ferrannini E, Cobelli C. The kinetics of insulin in man II. Role of the liver.  Diabetes Metab Rev. 1987;  3 365-397
• 27 Polonsky KS, Frank B, Pugh W, Addis A, Karrsion T, Meier P, Tager H, Rubenstein A. The limitations to and valid use of C-peptide as a marker of the secretion of insulin.  Diabetes. 1986;  35 379-386
• 28 Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance.  Diabetes. 1992;  41 368-377

Correspondence